Open AccessEffects of anti-osteoporosis therapy on plasma aldosterone and renin
Author(s) -
Qingfen Hu,
Kangla Liao,
Zhang Longwei,
Xiaoyu Shu,
Zhixin Xu,
Yuyang Qiu,
Qifu Li,
Shumin Yang
Publication year - 2020
Publication title -
journal of the renin-angiotensin-aldosterone system
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 46
eISSN - 1752-8976
pISSN - 1470-3203
DOI - 10.1177/1470320320928874
Subject(s) - medicine , osteoporosis , femoral neck , bone mineral , endocrinology , urology , aldosterone , parathyroid hormone , plasma renin activity , renin–angiotensin system , calcium , blood pressure
Objective: This study aimed to investigate the effect of anti-osteoporosis therapy on plasma aldosterone concentration (PAC), plasma renin concentration (PRC) and the aldosterone/renin ratio (ARR) in patients with postmenopausal osteoporosis.Methods: In 60 patients with postmenopausal osteoporosis, bone mineral density (BMD), PAC and PRC were measured before and after treatment with alendronate (70 mg/week, n=22) or recombinant human parathyroid hormone (20 μg/day, n=35) for 48 weeks.Results: PAC was negatively correlated with the T-score of lumbar spine BMD and femoral neck BMD (lumbar r=−0.386, p 37 pg/μIU, and the proportion decreased to 8% (5/57) after treatment.Conclusion: Treatment with alendronate or parathyroid hormone causes decreased PAC and increased PRC, resulting in a decreased ARR in postmenopausal women with osteoporosis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom